

**A2M Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP14790b****Specification**

---

**A2M Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [P01023](#)**A2M Antibody (C-term) Blocking Peptide - Additional Information****Gene ID 2****Other Names**

Alpha-2-macroglobulin, Alpha-2-M, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 5, A2M, CPAMD5

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**A2M Antibody (C-term) Blocking Peptide - Protein Information****Name** A2M**Synonyms** CPAMD5**Function**

Is able to inhibit all four classes of proteinases by a unique 'trapping' mechanism. This protein has a peptide stretch, called the 'bait region' which contains specific cleavage sites for different proteinases. When a proteinase cleaves the bait region, a conformational change is induced in the protein which traps the proteinase. The entrapped enzyme remains active against low molecular weight substrates (activity against high molecular weight substrates is greatly reduced). Following cleavage in the bait region, a thioester bond is hydrolyzed and mediates the covalent binding of the protein to the proteinase.

**Cellular Location**

Secreted.

**Tissue Location**

Secreted in plasma..

## **A2M Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

## **A2M Antibody (C-term) Blocking Peptide - Images**

## **A2M Antibody (C-term) Blocking Peptide - Background**

Alpha-2-macroglobulin is a protease inhibitor and cytokine transporter. It inhibits many proteases, including trypsin, thrombin and collagenase. A2M is implicated in Alzheimer disease (AD) due to its ability to mediate the clearance and degradation of A-beta, the major component of beta-amyloid deposits. [provided by RefSeq].

## **A2M Antibody (C-term) Blocking Peptide - References**

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010) Bruno, E., et al. Neurosci. Lett. 482(2):112-116(2010) Nalpas, B., et al. Gut 59(8):1120-1126(2010) Song, H., et al. Neurosci. Lett. 479(2):143-145(2010) Seriramalu, R., et al. Electrophoresis 31(14):2388-2395(2010)